CapVest Plans Majority Stake Acquisition in Stada Ending IPO

Bain Capital and Cinven, the private equity owners of German pharmaceutical company STADA Arzneimittel since 2017, have agreed to sell a majority stake to UK-based CapVest Partners, marking one of Europe's largest corporate takeovers of 2025. Under Bain and Cinven's ownership, STADA transformed from a traditional generics supplier into a diversified global healthcare platform with revenues exceeding €4 billion, driven by over 25 acquisitions and a strong focus on consumer healthcare, generics, and specialty pharmaceuticals. Despite prior considerations for an initial public offering, the company will remain privately held following the sale, with Bain and Cinven retaining minority stakes to signal continued confidence in STADA's growth. CapVest, with over 20 years of healthcare investment experience, plans to inject significant new capital to accelerate STADA's expansion in Germany and internationally. The transaction is expected to close in early 2026, pending regulatory approval. STADA's CEO Peter Goldschmidt praised CapVest as the ideal partner to support the company's next growth phase, reflecting a shared commitment to responsible ownership and long-term value creation.